Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy
Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg tri...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2018
|
| _version_ | 1826260558021656576 |
|---|---|
| author | Sánchez-Ramón, S Dhalla, F Chapel, H |
| author_facet | Sánchez-Ramón, S Dhalla, F Chapel, H |
| author_sort | Sánchez-Ramón, S |
| collection | OXFORD |
| description | Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar immunodeficiency and manifestations while they are not covered by the current IVIg indications. A potential beneficial strategy could be to vaccinate patients at monoclonal B lymphocytosis and monoclonal gammopathy of undetermined significance stages (for CLL and MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are attained. We have to re-emphasize the need for assessing and monitoring specific antibody responses; these are warranted to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review provides an overview of the current scenario, with a focus on prevention of infection in patients with hematological malignancies and the role of Ig replacement therapy. |
| first_indexed | 2024-03-06T19:07:33Z |
| format | Journal article |
| id | oxford-uuid:15aa0ee1-08c2-4d5b-b812-135ed3ee08e4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:07:33Z |
| publishDate | 2018 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:15aa0ee1-08c2-4d5b-b812-135ed3ee08e42022-03-26T10:26:44ZChallenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:15aa0ee1-08c2-4d5b-b812-135ed3ee08e4EnglishSymplectic Elements at OxfordFrontiers Media2018Sánchez-Ramón, SDhalla, FChapel, HPatients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar immunodeficiency and manifestations while they are not covered by the current IVIg indications. A potential beneficial strategy could be to vaccinate patients at monoclonal B lymphocytosis and monoclonal gammopathy of undetermined significance stages (for CLL and MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are attained. We have to re-emphasize the need for assessing and monitoring specific antibody responses; these are warranted to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review provides an overview of the current scenario, with a focus on prevention of infection in patients with hematological malignancies and the role of Ig replacement therapy. |
| spellingShingle | Sánchez-Ramón, S Dhalla, F Chapel, H Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title | Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title_full | Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title_fullStr | Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title_full_unstemmed | Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title_short | Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| title_sort | challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy |
| work_keys_str_mv | AT sanchezramons challengesintheroleofgammaglobulinreplacementtherapyandvaccinationstrategiesforhematologicalmalignancy AT dhallaf challengesintheroleofgammaglobulinreplacementtherapyandvaccinationstrategiesforhematologicalmalignancy AT chapelh challengesintheroleofgammaglobulinreplacementtherapyandvaccinationstrategiesforhematologicalmalignancy |